A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND

被引：0
|
作者：
O'Shaughnessy, Joyce
Basho, Reva
Lustberg, Maryam
Lyman, Gary H.
Prahladan, Manoj
James, Gareth D.
Varghese, Della
Lujan, Flavia
Tesch, Hans
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [2] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [3] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [4] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [5] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Schnog, John-John B.
    Samson, Michael J.
    Duits, Ashley J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144
  • [6] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [7] An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
    Modi, Shanu
    Salgado, Roberto
    Guarneri, Valentina
    Alagappan, Divi
    Dennis, Natalie
    Newell, Amy Hanlon
    Boran, Aislyn
    Morsli, Ouzna
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [8] Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer
    Kufel-Grabowska, Joanna
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05): : 377 - 381
  • [9] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] TRASTUZUMAB DERUXTECAN IS EFFECTIVE IN HER2-LOW BREAST CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (04) : 488 - 488
12345